The Kansas City Animal Health Investment Forum is considered one of the best platforms for enabling animal health start‐ups to make a plea to investors for funding. This year’s investment forum attracted even more presenting companies and investors than previous years. Animal Pharm analyst Sian Lazell attended to see which companies are seeking financial backing in 2015.
This year, 17 companies gathered in the Kansas City Animal Health Corridor (KCAHC) to showcase their products and technologies to potential investors.
Amongst others, some of the technologies presented included: alternatives to antibiotics; muscle atrophy and obesity treatments for pets; diagnostics; and cancer immunotherapies.
The presenting companies were seeking $500,000 to $20 million of funding. Most were also on the lookout for potential licensing and strategic partnerships.
Companies presenting in 2015
ELIAS Animal Health: Chief executive of the firm Tammie Wahaus said it is “working aggressively towards commercializing a cancer therapy as unique as the patient”, by offering a treatment which utilizes a patient’s own cancer cells.
ELIAS licensed the global rights to TVAX’s immunotherapy technology. The patent protected treatment is a two‐step process whereby a vaccine is used to induce an immune recognition response against cancer in the animal, then the veterinarian is provided with ex‐vivo activated T cells which are administered to the patient to fight its cancer.
ELIAS said current cancer treatments are limited and in 2014, around three million dogs were treated for the disease. The firm aims to gain 10% of the market space in five years.
It is currently looking for partnerships with investors to support research and development of the treatment, sales, manufacturing, marketing and distribution.